The interaction of small heat shock proteins (sHSPs) with the actin cytoskeleton has been described and some members of this family, e.g. chicken and murine HSP25 (HSP27), inhibit the polymerization of actin in vitro. To analyse the molecular basis of this interaction, we synthesized a set of overlapping peptides covering the complete sequence of murine HSP25 and tested the effect of these peptides on actin polymerization in vitro by fluorescence spectroscopy and electron microscopy. Two peptides comprising the sequences W43 to R57 (peptide 6) and I92 to N106 (peptide 11) of HSP25 were found to be potent inhibitors of actin polymerization. Phosphorylation of N-terminally extended peptide 11 at serine residues known to be phosphorylated in vivo resulted in decline of their inhibitory activity. Interestingly, peptides derived from the homologous peptide 11 sequence of murine aB-crystallin showed the same behaviour. The results suggest that both HSP25 and aB-crystallin have the potential to inhibit actin polymerization and that this activity is regulated by phosphorylation.
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Heat shock and other environmental and pathophysiologic stresses stimulate the synthesis of heat shock proteins (HSPs). These proteins enable cells to survive and recover from stressful conditions by as yet incompletely understood mechanisms. Small heat shock proteins (sHSPs) constitute one of the major heat shock protein families and are characterized by a molecular mass of 15±40 kDa. They share a homologous sequence of about 90 amino acids, called the`a-crystallin domain' because of its similarity with a sequence motif in the major eye lens protein aB-crystallin [1] . For sHSPs and aB-crystallin, which was also characterized as a sHSP [2] , similar structural and functional properties have been described (reviewed in [3, 4] ). sHSPs and aB-crystallin have the ability to form multimeric complexes with a molecular mass of up to < 800 kDa [5±8] . They occur in unphosphorylated and phosphorylated isoforms [9±13] , and show chaperoning activity [14, 15] . Furthermore, interactions with the cytoskeleton have been observed. For aB-crystallin interactions with actin and intermediate filament proteins have been described [16±21] , while HSP25 appears to interact primarily with actin filaments [8,21±27] . (In this paper the sHSP of mouse, chicken and human is referred to as HSP25. Other names used for this protein are HSP27 or HSP28.) HSP25 from chicken, mouse and yeast has been identified as inhibitor of actin polymerization in vitro [8, 22, 23] . The unphosphorylated monomer is the active form in this process, whereas phosphorylated monomers and high molecular weight complexes are inactive [8] . Several of the studies cited above and others support the idea that an interaction of sHSPs with actin also occurs in vivo. Overexpression of HSP25 was shown to stabilize microfilaments against deleterious effects of hyperthermia and cytochalasin D in murine NIH/3T3 cells [24] and to increase the concentration of F-actin at the cell cortex and the pinocytotic activity in Chinese hamster cell lines [25] . HSP25 was found to colocalize, depending on the developmental stage, with the actin cytoskeleton in rat Sertoli cells [26] and with the I-band of myofibrils in cardiomyocytes of rat and human heart [21] . Furthermore, overexpression of HSP25 influenced the organization of cortical actin in bovine endothelial cell lines [27] . In several reports it was shown that the association of HSP25 with actin was modulated by phosphorylation of the protein [8,25,27±30] . As the microfilament network is an early target of cellular stress and different signal transduction pathways, it is likely that sHSPs may contribute to the regulation of actin dynamics under normal and stressful conditions.
To gain more information on the interaction between sHSPs and actin we tested a set of overlapping peptides derived from the murine HSP25 sequence [31] for their ability to inhibit actin polymerization. Two of the 22 HSP25-derived peptides studied were found to be potent inhibitors of actin polymerization in vitro. N-terminal extension and phosphorylation at serine residues of these peptides known to be phosphorylated in vivo modulated their inhibitory activity. A similar behaviour was observed for homologous peptides derived from the murine aB-crystallin sequence. The data elucidate for the first time part of the molecular mechanism underlying the interaction of HSP25 and aB-crystallin with actin.
E X P E R I M E N T A L P R O C E D U R E S

Peptide synthesis
Peptides were synthesized by multiple solid phase peptide synthesis using the Fmoc chemistry procedure [32] on a PSSM-8 synthesizer (Shimadzu, Japan). Tentagel S RAM resin (RAPP Polymere GmbH, Germany) was used as carrier and 30% piperidine/dimethylformamide was used for Fmoc deprotection. All couplings were performed with O-(benzotriazol-1-yl)N,N H ,N H -tetramethyluronium tetrafluoroborate/1-hydroxybenzotriazole/N-methylmorpholine in dimethylformamide. Fmoc-Ser(PO(Obzl)-OH (Novabiochem, Switzerland) was used for the synthesis of phosphoserine peptides. After synthesis all peptides were acetylated, cleaved from the resin by trifluoracetic acid and the resulting N-terminally acetylated peptide amides were analysed by HPLC and purified up to 85±95% purity. All peptides were characterized by MS using a MALDI I mass spectrometer (Kratos, Manchester, UK) [33] . After lyophilization peptides were stored at 220 8C. Before use, peptides were dissolved in distilled water, and concentrations were determined by quantitative amino acid analysis using a Sykam Analysator (Sykam, Gilching, Germany). Aliquots were used for determination of extinction coefficients of all peptides by recording of UV spectra.
Preparation of pyrene actin
F-actin was prepared from rabbit muscle powder according to the procedure of Pardee and Spudich [34] [35] . Labelling was overnight with a freshly prepared solution of N-(1-pyrene)iodoacetamide (Molecular Probes) as described by Kouyama and Mihashi [36] . Labelled F-actin was depolymerized by extensive dialysis against buffer C (2 mm imidazole/HCl pH 7.0, 0.1 mm CaCl 2 , 0.2 mm Na 2 ATP, 1 mm dithiothreitol, 1 mm NaN 3 ) and centrifuged for 2 h at 150 000 g in a Beckman TLA 100.3 rotor (Beckman Instruments) to obtain purified labelled G-actin in the supernatant.
Preparation of actin nuclei
Unlabelled F-actin was depolymerized by extensive dialysis against buffer C and separated from traces of F-actin by centrifugation for 2 h at 150 000 g in a Beckman TLA 100.3 rotor. Actin nuclei were prepared from the supernatant according to the procedure described by Pollard [35] . Briefly, 0.1 vol. of a 10 Â buffer D solution (100 mm imidazole/HCl pH 7.0, 500 mm KCl) was added to unlabelled G-actin (1.5 mg´mL 21 ), polymerized overnight, diluted to 0.5 mg´mL 21 with buffer D and equilibrated for at least 3 h before use in the polymerization assay.
Actin polymerization
Actin polymerization was measured by enhancement of fluorescence of pyrene-labelled actin using a Shimadzu RF5001PC spectrofluorometer (Shimadzu Europe GmbH, Duisburg, Germany) equipped with a 150-W Xenon lamp and a temperature-controlled sample compartment under control of the rf software (Shimadzu). Fluorescence was monitored at an excitation wavelength of 365 nm (5 nm slit) and an emission wavelength of 407 nm (10 nm slit) for 10 min at 25 8C. If not mentioned otherwise, assay mixtures were prepared directly in the cuvette (Hellma microcuvette, 3 mm light path) in a total volume of 60 mL in the following manner: 5 mL labelled G-actin (final concentration 2 mm) and different amounts of peptides in 5 mL distilled water were diluted into 44 mL buffer C and equilibrated for 3 min at 25 8C in the spectrofluorometer. To initialize polymerization, 1 mL actin nuclei and 5 mL of a salt solution (600 mm KCl, 24 mm MgCl 2 ) were added and thoroughly mixed. Recording was started within 10 s after addition of the latter. Under these conditions actin polymerization starts almost immediately and follows largely a linear kinetics up to 15 min. Addition of nuclei alone could not induce polymerization and addition of salt alone resulted in an extended lag period of about 5 min (Fig. 1A ). For estimation of the stoichiometry of inhibition, slopes were determined from linear regression of the curves up to 5 min after start of the reaction, i.e. within the linear range of the slopes. They were calculated as percentage of inhibition of actin polymerization as compared to the control.
Electron microscopy
In this assay, conditions of polymerization were modified, in that nuclei were omitted in order to visualize only newly formed actin filaments. Furthermore, mixtures were incubated for 15 min before processing for electron microscopy because of the prolonged lag-period in the absence of actin nuclei (cf. Fig. 1A , curve 2). Samples were negatively stained with 1% uranyl formate using the double carbon film technique as described previously [7] . Micrographs were taken with an EM 910 electron microscope (LEO, Oberkochen, Germany) at 80 kV and a magnification of 50 000Â.
R E S U L T S
Inhibition of actin polymerization by murine HSP25-derived peptides
To identify HSP25-derived fragments which interact with actin, a set of peptides was synthesized comprising the entire murine HSP25 sequence ( Table 1 ). The size of the peptides ranged from 12 to 15 amino-acid residues with overlapping stretches of five to seven residues. These peptides were tested with respect to their ability to inhibit actin polymerization in vitro in a spectrofluorometric assay as described in Experimental procedures. When used at 20-fold molar excess over G-actin, only two peptides had an inhibitory effect on actin polymerization: peptide 6 (W43-R57) and peptide 11 (I92-N106). All other peptides had no influence under these conditions. The dependence of actin polymerization inhibition on the concentration of both peptides is demonstrated in Fig. 1B±D . the slopes of the curves obtained within 5 min of initializing the reaction. Curve 1 (peptide 11) and curve 2 (peptide 6) reveal that 50% inhibition of actin polymerization is achieved at peptide to G-actin ratios of 2.5 : 1 and 10 : 1, respectively.
To verify that the spectrofluorometric data reflect inhibition of formation of actin filaments, electron microscopic experiments were performed in parallel. As shown in control experiments without peptide ( Fig. 2A) , actin filaments of several micrometers length are loosely distributed in the G-actin background, whereas in the presence of a 10-fold molar excess of peptide 11 no actin filaments are observed (Fig. 2B) . The same result was obtained when using a 20-fold molar excess of peptide 6 (not shown). Thus, the spectrofluorometric data are confirmed by electron microscopy.
Inhibition of actin polymerization by variants of murine HSP25-derived peptide 11
Further studies were performed with modifications of the most effective peptide 11 of murine HSP25. To analyse whether the amino acid composition of peptide 11, irrespective of the position of each amino-acid residue, or the specific position of each residue determines its interaction with actin, a scrambled control peptide ( Table 2 , peptide 11c) was synthesized. In designing this peptide, amino-acid residues known for their ability to participate in specific secondary structural elements were exchanged in their position. When using this peptide at 20-fold molar excess over G-actin, no effect on actin polymerization was observed (data not shown) indicating the specificity of the interaction of peptide 11 with actin.
In the following study, peptide 11 was modified by deleting amino-acid residues from both the N-and the C-terminus to identify residues involved in interaction with actin. Results of experiments carried out with these peptides in the actin polymerization assay are shown partially in Fig. 3A and summarized in Table 2 (abbreviations used for these peptides are also indicated in Table 2 ). Stepwise deletion of the first three amino-acid residues IRQ from the N-terminus of peptide 11 (peptides 11DN1, 11DN2, 11DN3) gradually reduced its activity to < 25%, < 5% and 0%, respectively (peptide 11DN3 see Fig. 3A, curve 2) . Surprisingly, deletion of the first six amino-acid residues IRQTAD (peptide 11DN6) partially restored the inhibitory activity, resulting in < 20% activity compared with peptide 11 (Fig. 3A, curve 6 ). The increased inhibitory activity of peptide 11DN6 compared to peptide 11DN3 suggests that the amino-acid residues TAD function as a linker between Table 2 . Compilation of various peptide 11-related sequences used in the actin polymerization assay. Peptides were derived from murine HSP25 and aB-crystallin sequences. A number of peptides was obtained by N-and C-terminal deletion and by N-terminal extension of peptide 11-related sequences (see also Fig. 3 ). Residue numbers indicate N-and C-terminal positions of the peptides in the amino-acid sequence of the protein. S indicates serines that are phosphorylated in the corresponding peptides (P). Activity of the peptides is related to that of the HSP25 peptide 11 which is set to 100% (see also Fig. 4) . Numbers in parentheses refer to phosphorylated peptides.
Peptide
Residues Sequence Activity two terminal motifs the coordination of which is necessary for an effective inhibition of actin polymerization (see Discussion). After deletion of the N-terminal amino-acid residues IRQ, this linker sequence seems to flex freely and thus to hinder sterically binding of peptide 11DN3, thereby reducing the inhibitory activity of the peptide in the actin polymerization assay. Deletion of the linker residues TAD from this peptide, however, resulted in improved binding and increased inhibitory activity. Further deletion from the N-terminus comprising the residues IRQTADRWR (peptide 11DN9) decreased the inhibitory activity to < 5% compared with peptide 11 (Fig. 3A, curve 4) . In comparison, deletion of amino-acid residues from the C-terminus of peptide 11 was slightly less effective in reducing the inhibitory activity of peptide 11. Deletion of the residues LDVN (peptide 11DC4) and VSLDVN (peptide 11DC6) reduced the inhibitory activity to < 10% and < 5%, respectively, of that of peptide 11 (Fig. 3A , curves 5 and 3). Further deletion from the C-terminus comprising the residues WRVSLDVN (peptide 11DC8) completely abolished the inhibitory activity of peptide 11. Also no inhibitory activity displayed a peptide where both the Nand the C-termini were deleted (11DN4DC3). These data indicate that both the N-terminal (IRQ) and the C-terminal (WRVSLDVN) amino-acid residues of peptide 11 are involved in its inhibitory activity. For full activity, however, both the N-and the C-termini are required. That each terminus per se is not sufficient for an effective inhibitory activity is supported by the fact that the sequences IRQ and SLVDN are also included in the neighbouring peptides 10 and 12, which were inactive.
Because of the reported interaction of the closely related sHSP aB-crystallin with actin (see Introduction), an aB-crystallin-derived peptide corresponding to peptide 11 of HSP25 was synthesized (peptide 11aB). Its sequence was defined by sequence alignment of murine HSP25 and aB-crystallin as shown in Fig. 4 . However, peptide 11aB had no effect on actin polymerization when used at 20-fold molar excess to actin and was inactive even at 40-fold molar excess (data not shown).
Phosphorylation affects the activity of HSP25-and aB-crystallin-derived peptides
Phosphorylation upon stress is one of the most prominent features of sHSPs, and it is known that phosphorylation of HSP25 modulates its effect on actin polymerization (see Discussion). To analyse the effect of phosphorylation on the actin polymerization inhibitory activity of HSP25-and aB-crystallin-derived peptides, we took advantage of the fact that some of the phosphorylation sites of these proteins are located N-terminally in close vicinity to peptide 11 (or the corresponding aB-crystallin-derived peptide; see Fig. 4 ). Therefore, the N-terminally extended HSP25-derived peptide (111N16) as well as the aB-crystallin-derived peptide (11aB1N16) were synthesized. These peptides include known phosphorylation sites at S86 (murine HSP25 [11] ); and S59 (murine aB-crystallin [9, 13] ); (see Table 2 and Fig. 4) . From each peptide, the unphosphorylated as well as the phosphorylated form (111N16P, 11aB1N16P) were synthesized. As shown in Fig. 3B , the unphosphorylated HSP25 peptide 111N16 (curve 5) inhibited actin polymerization effectively at 10-fold molar excess over G-actin, with < 50% of the inhibitory activity of peptide 11 ( Table 2 , cf. Fig. 1B ). Reduced efficacy of peptide 111N16 compared with peptide 11 may be due to higher flexibility of the N-terminal region of the molecule which may sterically hinder proper binding to actin (see Discussion). When the phosphorylated form of this peptide, 111N16P, was used, the activity was reduced to < 25% compared with peptide 11 (a 50% reduction in inhibitory activity compared with peptide 111N16) (Fig. 3B, curve 2) . Interestingly, in contrast with peptide 11aB, also the N-terminally extended form of the aB-crystalline peptide, 11aB1N16, demonstrated an inhibitory effect on actin polymerization (Fig. 3B,  curve 4) , which was comparable to the effect of the homologous HSP25-derived peptide (Table 2 ). Moreover, the activity was reduced when the phosphorylated form of this peptide, 11aB1N16P, was used (Fig. 3B, curve 3) , the extent of reduction again being comparable to that of the homologous HSP25 peptide 111N16P (Table 2 ). These data are remarkable in two aspects: (a) synthetic peptides derived from N-terminally extended peptide 11-like sequences of aB-crystallin inhibit actin polymerization in vitro like those of HSP25; and (b) phosphorylation of these peptides results in a reduction of their actin polymerization inhibitory activity. This behaviour is similar to that of intact native HSP25 (cf [8] ).
D I S C U S S I O N
This study provides the first evidence for a direct interaction of defined sequence segments of the small heat shock proteins HSP25 and aB-crystallin with actin thus specifying previous results about the function of HSP25 as inhibitor of actin polymerization [22] and implying a similar function for aB-crystallin. In particular, two regions of murine HSP25 have been identified which inhibit polymerization of actin effectively in vitro. Synthetic peptides comprising these sequences (peptides 6 and 11) inhibit actin polymerization half maximally at 10-and 2.5-fold molar excess over G-actin, respectively, compared with 0.1-to 0.2-fold molar excess of the isolated protein [8, 22] . Thus, 10-to 100-fold higher amounts of the peptides are necessary to exert the same effects as the native protein. Similar relationships in inhibition of actin polymerization between actin-binding peptides and intact proteins have been described for other proteins: about 10-fold higher amounts of the actin-binding dodecapeptide of cofilin, an F-actin Fig. 4 . Alignment of HSP25 and aB-crystallin sequences. Asterisks in the consensus line indicate identical amino-acid residues, colons indicate conserved substitutions and dots indicate semiconserved substitutions. Arrows indicate the phosphorylation sites of HSP25 (double arrow) and aB-crystallin (arrow). Sequences of peptide 6 and extended peptide 11 are shown in bold letters. The N-terminus of the a-crystallin domain is marked by an asterisk. Sequences are from murine HSP25 (GenBank Accession Number P14602) and murine aB-crystallin (GenBank Accession Number P23927).
side-binding and depolymerizing protein [37] , and the actin-binding 30-residue fragment of thymosin b4, a G-actin sequestering protein [38] , are necessary to achieve the same extent of inhibition as the intact protein. Lower efficacy of peptides compared with whole proteins may be due to the fact that peptides in general show a lower degree of higher ordered structure which may result in lower binding affinity, whereas in the whole protein these sequence segments are stabilized by neighbouring sequence elements and by interaction with other protein domains. The inhibitory effect of murine HSP25 peptide 11 on actin polymerization is < 10-fold and threefold higher than that of the cofilin- [37] and thymosin b4-derived peptides [38] . Similarly, the inhibitory activity of murine HSP25 peptide 11 is about sixfold higher than that of a peptide (27-mer) derived from actin binding protein (ABP-120), an actin filament cross-linking protein of Dictyostelium discoideum, which displays 50% inhibition of actin polymerization at a 14-fold molar excess of the peptide over G-actin [39] . Furthermore, an actin-binding peptide (30-mer) derived from the N-terminus of actobindin from Acanthamoeba castellani was found to cause 50% inhibition of actin polymerization at about sevenfold molar excess of the peptide over G-actin [38] , thus being three times less effective than the murine HSP25-derived peptide 11. Hence, HSP25-derived peptides 6 and 11 belong to the most active peptides inhibiting actin polymerization according to our knowledge.
Sequence comparison with actin-binding sites of other proteins reveals that no sequence homology exists between the HSP25-and aB-crystallin-derived peptides with actin polymerization inhibiting activity and the above-mentioned actin-binding dodecapeptide of cofilin and homologous sequences in the related proteins destrin, ADF and depactin [37] . Furthermore, no sequence similarity has been found to the actin-binding site of ABP-120, a conserved sequence which is also found in a-actinin, b-spectrin, dystrophin and fimbrin [39] . The same is true for the actin-binding sites of actobindin and thymosin b4 [38] , the b subunit of CapZ [40] and proteins of the ezrin family [41] . Moreover, the actin-binding hexapeptide motif present in actobindin and thymosin b4 which also exists in a number of other actinbinding proteins like a-actinin, fimbrin, plastin, villin, myosin heavy chain and tropomyosin [42] is not found in HSP25 and aB-crystallin. Thus, sHSPs seem to represent a new family of actin-binding proteins. This interpretation is supported by recent results indicating that a further sHSP, rat HSP20, associates with actin [43] .
The data about the inhibitory activity of HSP25-derived peptides can be correlated with data about the crystal structure of HSP16.5, a homologous sHSP from the archaebacterium Methanococcus jannaschii [44] . As evident from the crystal structure, the region homologous to peptide 11 of HSP25 is composed of two b strands in antiparallel orientation (b2, b3 in HSP16.5) connected by a turn of three amino-acid residues. Interestingly, this turn corresponds to residues TAD of murine peptide 11 proposed to act as a linker between the identified N-and C-terminal motifs involved in actin binding (see Results). It is very likely that this proposed linker sequence allows peptide 11 to adopt a conformation, which enables appropriate interaction with the actin molecule. Furthermore, it can be concluded from the crystal structure of Hsp16.5 that the region of the extended peptide 11 is most probably involved in intersubunit contacts in high molecular weight complexes of HSP25 as several of the amino-acid residues located in the homologous region of HSP16.5 (S31 to P61) contribute to contacts between subunits along the twofold axis of the complexes (see Kim et al. [44] ). The region homologous to the HSP25-derived peptide 6, however, is missing from HSP16.5. According to the crystallographic data the N-terminus of HSP16.5 is located in the interior of the high molecular weight complexes, and it is likely that this also applies for the N-terminal region of HSP25. Thus, in high molecular weight complexes of HSP25 the aminoacid residues of peptides 6 and 11 are most probably buried and not accessible to interact with actin. In contrast, in HSP25 monomers these regions seem to be accessible and consequently they may interact with actin. This confirms previous results which indicated that only HSP25 monomers but not high molecular weight complexes of HSP25 inhibit actin polymerization in vitro [8] .
Comparison of the inhibitory activity of peptides derived from homologous sequences of HSP25 and aB-crystallin showed a comparable extent of inhibition by the N-terminally extended peptides 111N16. These data suggest that not only HSP25, but also aB-crystallin acts as an inhibitor of actin polymerization and that the activity of both proteins is at least partially mediated by these sequence segments. The lower efficacy of peptide 111N16, compared with peptide 11, is likely to have the same causes as discussed above. Based on the crystal structure of HSP16.5 ( [44] , and see above), it can be concluded that the N-terminus of peptide 111N16 contains a short b strand (b1) and is partially unstructured. As b1 belongs to another b sheet than b2 and b3 of peptide 11, it is very unlikely that peptide 111N16 can adopt the correct tertiary structure present in the whole protein. Protection of binding sites and/or sterical hindrance by the flexible N-terminus of the 32-mer could result in lower efficacy of peptide 111N16 compared with peptide 11. Differences in the inhibitory potential of the HSP25-derived peptide 11 and the aB-crystallin-derived peptide 11aB, on the other hand, may reflect cell-type specific mechanisms of regulation of the actin-binding ability of HSP25 and aB-crystallin which may occur through the interaction with different sHSP-binding proteins discovered recently [26, 45] . Differential location of both proteins in rat and human heart [21] and rat kidney [46] supports this view.
Another interesting result described here is the reduced inhibitory activity of phosphorylated vs. unphosphorylated HSP25-and aB-crystallin peptides. This finding confirms previous results obtained with native murine HSP25 in vitro showing that unphosphorylated but not phosphorylated HSP25 monomers inhibit actin polymerization [8] . Furthermore, there is growing evidence about phosphorylationdependent effects of HSP25 on the organization of microfilaments in vivo. Transfection or microinjection of different cell types with wild-type or nonphophorylatable HSP25 demonstrated, that only wild-type HSP25 protected the microfilament network against the deleterious effects of hyperthermia [24, 30] , cytochalasin D [24] , free oxygen radicals [47] and cholecystokinin [48] . Protein phosphatase inhibitors and heat preconditioning were shown to prevent HSP25 dephosphorylation and F-actin disruption [29, 49] . Pinocytosis activity [25] , amount of membrane-associated F-actin [27] and cell migration [28] were shown to depend on the presence of phosphorylatable HSP25. Obviously, phosphorylation of HSP25 is a prerequisite for rapid modulation of the actin cytoskeleton.
In comparison, data about interaction of aB-crystallin with actin are more rare. It was demonstrated previously that aB-crystallin colocalizes with microfilaments in cultured lens cells [50] and with the I-band of myofibrils in cardiomyocytes of rat and human heart [21] . Furthermore, aB-crystallin was found to bind to actin by affinity chromatography [16, 17] and cosedimentation assays [17] . In addition, antisense experiments showed a disorganized microfilament network in cultured glial cells after reduction of aB-crystallin expression [19] . With respect to the influence of phosphorylation on the interaction of aB-crystallin with actin it was described that phosphorylated aB-crystallin was less effective in suppression of cytochalasin-induced depolymerization of actin filaments than the unphosphorylated form [20] , in this respect aB-crystallin being comparable to HSP25. These findings are in accordance with our results on the interaction of aB-crystallin-derived peptides with actin and the regulation of their activity by phosphorylation. Interestingly, the different phosphorylation sites of aB-crystallin are phosphorylated by different kinases, and only S59, which is included in the extended peptide 11 tested in our assays, is phosphorylated by MAPKAP kinase-2 [51] , which also phosphorylates the homologous phosphorylation site S86 in murine HSP25 [52] . Furthermore, it was shown that phosphorylation of aB-crystallin and HSP25 occurs in response to similar stressors in HeLa cells [53] . Obviously, in accordance with our in vitro results, regulation of the interaction of HSP25 and aB-crystallin with actin in vivo seems to occur through the same signal transduction cascade(s). Finally, it should be mentioned that regulation of activity by phosphorylation has also been observed for several other actin-binding proteins, e.g. synapsin [54] , caldesmon [55] , actin depolymerizing factor [56] and cofilin [57] which are unable to bind to actin in their phosphorylated states.
In conclusion, this work provides the first data about the molecular mechanism of the interaction of the small heat shock proteins HSP25 and aB-crystallin with actin. It describes actin-binding sites involved in inhibition of actin polymerization and provides data implying that the actinpolymerization inhibiting activity of both proteins is reduced by phosphorylation. Thus, HSP25 and aB-crystallin are characterized as actin-binding proteins the activity of which is regulated by phosphorylation, a feature that may also apply to other sHSPs.
